# Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer

Study · id `cardio:ct-nct05460416` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05460416](<https://clinicaltrials.gov/study/NCT05460416>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05460416

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.

## Technical summary

Registry record NCT05460416. Randomized; single masking; primary purpose prevention. Start 2022-10-25 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 276 participants (planned count; ClinicalTrials.gov record NCT05460416, source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)
- Started: 2022-10-25 (actual) (ClinicalTrials.gov record NCT05460416, source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)
- Primary completion: 2025-12-31 (anticipated) (ClinicalTrials.gov record NCT05460416, source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT05460416, source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)
- Countries: Belgium (ClinicalTrials.gov record NCT05460416, source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05460416-2025-02-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer
- Acronym: TePPAFET
- Condition: Embryo Transfer
- Condition: Hypertension, Pregnancy Induced
- Intervention (Drug): Acetylsalicylic acid
- Lead sponsor: Centre Hospitalier Universitaire de Liege
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)

## Provenance

Content hash: d2c51e03dd5e219079fab3936e0b714dfd7536448615c599bfe5ca5291e62542
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
